2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
19
Neoplasms
11
Polycystic Ovary Syndrome
9
Neoplasm Metastasis
4
Multiple Myeloma
4
Melanoma
4
Vomiting
3
Prostatic Neoplasms
3
Leukemia, Myeloid, Acute
3
Leiomyoma
3
Head and Neck Neoplasms
3
Endometrial Neoplasms
3
Triple Negative Breast Neoplasms
2
Solid Tumors
2
Skin Neoplasms
2
Sarcoma
2
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Peripheral Nervous System Diseases
2
Ovarian Neoplasms
2
Obesity
2
Nausea
2
Myofibroma
2
Lung Neoplasms
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, B-Cell
2
Leukemia
2
Insulin Resistance
2
Inflammation
2
Infertility, Female
2
Interventions
Magnetic Resonance Spectroscopy
16
Hydroxyurea
7
Everolimus
7
Bevacizumab
7
lutetium Lu 177 dotatate
6
gallium Ga 68 dotatate
6
Radiosurgery
6
Proton Therapy
6
Specimen Handling
5
pembrolizumab
4
Surveys and Questionnaires
4
Surgical Procedures, Operative
4
Radiotherapy
4
Imatinib Mesylate
4
Cyclophosphamide
4
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
4
aldesleukin
3
abemaciclib
3
Tranexamic Acid
3
Temozolomide
3
Sunitinib
3
Sodium Chloride
3
Radiotherapy, Intensity-Modulated
3
Observation
3
Nivolumab
3
Ga(III)-DOTATOC
3
90Y-octreotide, DOTA-Tyr(3)-
3
vistusertib
2
trametinib
2
ribociclib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Meningioma
×
Tablets
×
Clear all
NCT06275919
2026-05-13
MIRAGE
Istituto Oncologico Veneto IRCCS
Phase 2
Recruiting
104 enrolled